Friday, October 16, 2015

Partnerships, collaboration and innovation

By Barbara Tardiff, Pfizer

Bringing new therapies to patients is a complex, multi-faceted effort that intrinsically requires collaboration, innovation and partnership. There are many challenges that need to be overcome during the therapy development process, and while many pharmaceutical companies are comfortable creating innovative scientific solutions, they are not all so comfortable innovating in the clinical trials process and operations. And historically, service companies have not seen innovation as part of their scope.

Successful partnerships are needed to develop and maintain a stable pattern of continuous innovation.  Clinical trial leadership and governance need to be engaged and open to innovation and intent on building trusting relationships with partners. Building and managing complex collaborations involving three or more partners is a pivotal challenge that requires particularly strong and effective leadership.

Without substantive and regular innovation of processes and operations, the number of new therapies and the speed with which they are made available will be greatly limited. In general, the challenges associated with innovation must be solved through creative engagement, and not through regulation. However, regulators can encourage innovation by incorporating appropriate levels of nuance into the application of regulations and being open to varying approaches to ensuring that marketed therapeutics are safe and efficacious.

PCT-Europe plays a pivotal role in bringing partners and potential partners together in a forum that encourages the sharing of ideas and approaching challenges from fresh perspectives. These issues will feature prominently in the very popular Outsourcing and Partnership Forum workshops that will be hosted at this year’s PCT Europe in Hamburg.

No comments: